Apnimed Announces $62.5 Million Series C Financing to Advance Development of Novel Pharmaceutical…
Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today that…
Read More...
Read More...
